Rizatriptan 10-mg ODT for early treatment of migraine and impact of migraine education on treatment response

Roger K. Cady, Vincent T. Martin, Gilles Géraud, Anthony Rodgers, Ying Zhang, Andrew P. Ho, Carolyn M. Hustad, Tony W. Ho, Kathryn M. Connor, Karen E. Ramsey

Research output: Contribution to journalArticle

Abstract

Objective. - To examine the efficacy of rizatriptan 10-mg orally disintegrating tablet (ODT) for treating migraines of mild intensity soon after onset, with or without patient-specific migraine education. Background. - Studies have shown rizatriptan tablet efficacy in early migraine treatment. Methods. - In this randomized, placebo-controlled, double-blind, factorial design study, adults with a history of migraine were assigned to rizatriptan 10-mg ODT ± patient education (personalized summary of early migraine signs and symptoms) or placebo ± patient education in a 1 : 1 : 1 : 1 ratio. Patients were instructed to treat 1 attack at the earliest time they knew that their headache was a migraine, while pain was mild. During the next 24 hours, patients assessed pain severity, associated symptoms, functional disability, use of rescue medication, and treatment satisfaction. The primary endpoint was pain freedom at 2 hours; a key secondary endpoint was 24-hour sustained pain freedom. Results. - Of 207 patients randomized to treatment, 188 (91%) treated a study migraine. Significantly more patients taking rizatriptan reported pain freedom at 2 hours compared with placebo (66.3% vs 28.1%, P

Original languageEnglish (US)
Pages (from-to)687-696
Number of pages10
JournalHeadache
Volume49
Issue number5
DOIs
StatePublished - May 2009
Externally publishedYes

Fingerprint

Migraine Disorders
Tablets
Education
Pain
Placebos
Patient Education
Therapeutics
rizatriptan
Signs and Symptoms
Headache

Keywords

  • Early treatment
  • Education
  • Efficacy
  • Migraine
  • Rizatriptan

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Cady, R. K., Martin, V. T., Géraud, G., Rodgers, A., Zhang, Y., Ho, A. P., ... Ramsey, K. E. (2009). Rizatriptan 10-mg ODT for early treatment of migraine and impact of migraine education on treatment response. Headache, 49(5), 687-696. https://doi.org/10.1111/j.1526-4610.2009.01412.x

Rizatriptan 10-mg ODT for early treatment of migraine and impact of migraine education on treatment response. / Cady, Roger K.; Martin, Vincent T.; Géraud, Gilles; Rodgers, Anthony; Zhang, Ying; Ho, Andrew P.; Hustad, Carolyn M.; Ho, Tony W.; Connor, Kathryn M.; Ramsey, Karen E.

In: Headache, Vol. 49, No. 5, 05.2009, p. 687-696.

Research output: Contribution to journalArticle

Cady, RK, Martin, VT, Géraud, G, Rodgers, A, Zhang, Y, Ho, AP, Hustad, CM, Ho, TW, Connor, KM & Ramsey, KE 2009, 'Rizatriptan 10-mg ODT for early treatment of migraine and impact of migraine education on treatment response', Headache, vol. 49, no. 5, pp. 687-696. https://doi.org/10.1111/j.1526-4610.2009.01412.x
Cady, Roger K. ; Martin, Vincent T. ; Géraud, Gilles ; Rodgers, Anthony ; Zhang, Ying ; Ho, Andrew P. ; Hustad, Carolyn M. ; Ho, Tony W. ; Connor, Kathryn M. ; Ramsey, Karen E. / Rizatriptan 10-mg ODT for early treatment of migraine and impact of migraine education on treatment response. In: Headache. 2009 ; Vol. 49, No. 5. pp. 687-696.
@article{728fe655dac24be388904b3ac41ba6c8,
title = "Rizatriptan 10-mg ODT for early treatment of migraine and impact of migraine education on treatment response",
abstract = "Objective. - To examine the efficacy of rizatriptan 10-mg orally disintegrating tablet (ODT) for treating migraines of mild intensity soon after onset, with or without patient-specific migraine education. Background. - Studies have shown rizatriptan tablet efficacy in early migraine treatment. Methods. - In this randomized, placebo-controlled, double-blind, factorial design study, adults with a history of migraine were assigned to rizatriptan 10-mg ODT ± patient education (personalized summary of early migraine signs and symptoms) or placebo ± patient education in a 1 : 1 : 1 : 1 ratio. Patients were instructed to treat 1 attack at the earliest time they knew that their headache was a migraine, while pain was mild. During the next 24 hours, patients assessed pain severity, associated symptoms, functional disability, use of rescue medication, and treatment satisfaction. The primary endpoint was pain freedom at 2 hours; a key secondary endpoint was 24-hour sustained pain freedom. Results. - Of 207 patients randomized to treatment, 188 (91{\%}) treated a study migraine. Significantly more patients taking rizatriptan reported pain freedom at 2 hours compared with placebo (66.3{\%} vs 28.1{\%}, P",
keywords = "Early treatment, Education, Efficacy, Migraine, Rizatriptan",
author = "Cady, {Roger K.} and Martin, {Vincent T.} and Gilles G{\'e}raud and Anthony Rodgers and Ying Zhang and Ho, {Andrew P.} and Hustad, {Carolyn M.} and Ho, {Tony W.} and Connor, {Kathryn M.} and Ramsey, {Karen E.}",
year = "2009",
month = "5",
doi = "10.1111/j.1526-4610.2009.01412.x",
language = "English (US)",
volume = "49",
pages = "687--696",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Rizatriptan 10-mg ODT for early treatment of migraine and impact of migraine education on treatment response

AU - Cady, Roger K.

AU - Martin, Vincent T.

AU - Géraud, Gilles

AU - Rodgers, Anthony

AU - Zhang, Ying

AU - Ho, Andrew P.

AU - Hustad, Carolyn M.

AU - Ho, Tony W.

AU - Connor, Kathryn M.

AU - Ramsey, Karen E.

PY - 2009/5

Y1 - 2009/5

N2 - Objective. - To examine the efficacy of rizatriptan 10-mg orally disintegrating tablet (ODT) for treating migraines of mild intensity soon after onset, with or without patient-specific migraine education. Background. - Studies have shown rizatriptan tablet efficacy in early migraine treatment. Methods. - In this randomized, placebo-controlled, double-blind, factorial design study, adults with a history of migraine were assigned to rizatriptan 10-mg ODT ± patient education (personalized summary of early migraine signs and symptoms) or placebo ± patient education in a 1 : 1 : 1 : 1 ratio. Patients were instructed to treat 1 attack at the earliest time they knew that their headache was a migraine, while pain was mild. During the next 24 hours, patients assessed pain severity, associated symptoms, functional disability, use of rescue medication, and treatment satisfaction. The primary endpoint was pain freedom at 2 hours; a key secondary endpoint was 24-hour sustained pain freedom. Results. - Of 207 patients randomized to treatment, 188 (91%) treated a study migraine. Significantly more patients taking rizatriptan reported pain freedom at 2 hours compared with placebo (66.3% vs 28.1%, P

AB - Objective. - To examine the efficacy of rizatriptan 10-mg orally disintegrating tablet (ODT) for treating migraines of mild intensity soon after onset, with or without patient-specific migraine education. Background. - Studies have shown rizatriptan tablet efficacy in early migraine treatment. Methods. - In this randomized, placebo-controlled, double-blind, factorial design study, adults with a history of migraine were assigned to rizatriptan 10-mg ODT ± patient education (personalized summary of early migraine signs and symptoms) or placebo ± patient education in a 1 : 1 : 1 : 1 ratio. Patients were instructed to treat 1 attack at the earliest time they knew that their headache was a migraine, while pain was mild. During the next 24 hours, patients assessed pain severity, associated symptoms, functional disability, use of rescue medication, and treatment satisfaction. The primary endpoint was pain freedom at 2 hours; a key secondary endpoint was 24-hour sustained pain freedom. Results. - Of 207 patients randomized to treatment, 188 (91%) treated a study migraine. Significantly more patients taking rizatriptan reported pain freedom at 2 hours compared with placebo (66.3% vs 28.1%, P

KW - Early treatment

KW - Education

KW - Efficacy

KW - Migraine

KW - Rizatriptan

UR - http://www.scopus.com/inward/record.url?scp=65449135596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65449135596&partnerID=8YFLogxK

U2 - 10.1111/j.1526-4610.2009.01412.x

DO - 10.1111/j.1526-4610.2009.01412.x

M3 - Article

C2 - 19472447

AN - SCOPUS:65449135596

VL - 49

SP - 687

EP - 696

JO - Headache

JF - Headache

SN - 0017-8748

IS - 5

ER -